Olaparib.
Olaparib is used to treat BReast CAncer susceptibility protein (BRCA)-associated, platinum-sensitive ovarian cancer. Olaparib inhibits poly(ADP-ribose) polymerase, thereby blocking the repair of single-strand DNA breaks. This results in synthetic lethality in BRCA-associated cancer cells, which have a dysfunction of another DNA repair pathway - homologous recombination.
Centre for Human Drug Research, Leiden, the Netherlands.
S C
SC
Goulooze
Centre for Human Drug Research, Leiden, the Netherlands.|Leiden University Medical Center, Leiden, the Netherlands.
A F
AF
Cohen
Centre for Human Drug Research, Leiden, the Netherlands.|Leiden University Medical Center, Leiden, the Netherlands.
R
R
Rissmann
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004260:DNA Repair / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010793:Phthalazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000067856:Poly(ADP-ribose) Polymerase Inhibitors / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D010793:Phthalazines; D010879:Piperazines; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; C531550:olaparib